Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer
February 22nd 2016James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
Read More